DUBLIN – Domain Therapeutics SA and Medixci Ventures have teamed up to form Mavalon Therapeutics SA, a single-asset play with €9 million (US$10 million) funding and a preclinical Parkinson's disease program based on a series of orally available positive allosteric modulators (PAMs) of the metabotropic glutamate receptor 3 (mGluR3).